Safety and Efficacy of Ruxolitinib in Myelofibrosis Patients Without Splenomegaly

British Journal of Haematology - United Kingdom
doi 10.1111/bjh.13758
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Wiley

Related search

Efficacy of Ruxolitinib for Myelofibrosis

Expert Opinion on Pharmacotherapy
MedicinePharmacology
2014English

Ruxolitinib as an Emerging Treatment in Myelofibrosis

Blood and Lymphatic Cancer: Targets and Therapy
2013English

Definition and Management of Ruxolitinib Treatment Failure in Myelofibrosis

Blood Cancer Journal
OncologyHematology
2014English

Ruxolitinib for Myelofibrosis–An Update of Its Clinical Effects

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2013English

Effects of Ruxolitinib Treatment on Metabolic and Nutritional Parameters in Patients With Myelofibrosis From COMFORT-I

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2015English

Critical Appraisal of the Role of Ruxolitinib in Myeloproliferative Neoplasm-Associated Myelofibrosis

OncoTargets and Therapy
OncologyPharmacology
2015English

U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients With Intermediate and High-Risk Myelofibrosis

Clinical Cancer Research
Cancer ResearchOncology
2012English

JAK Inhibition With Ruxolitinib Versus Best Available Therapy for Myelofibrosis

New England Journal of Medicine
Medicine
2012English

Retrospective Review of Safety and Efficacy of Percutaneous Gastrostomy Placement Without Gastropexy in Extremely Sick Patients

Journal of Vascular and Interventional Radiology
Nuclear MedicineRadiologyCardiologyCardiovascular MedicineImagingMedicine
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy